Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease A Comprehensive Biomarker Analysis

被引:0
作者
Bais, Thomas [1 ]
Knol, Martine G. E. [1 ]
Xue, Laixi [2 ]
Geertsema, Paul [1 ]
Vart, Priya [3 ]
Reichel, Franz [4 ,5 ]
Arjune, Sita [4 ,5 ]
Mueller, Roman-Ulrich [4 ,5 ]
Dekker, Shosha E. I. [6 ]
Salih, Mahdi [2 ]
Meijer, Esther [1 ]
Gansevoort, Ron T. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr, Dept Internal Med, Div Nephrol, Groningen, Netherlands
[2] Erasmus MC, Dept Internal Med, Div Nephrol & Transplantat, Rotterdam, Netherlands
[3] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[4] Univ Cologne, Fac Med, Dept Internal Med 2, Cologne, Germany
[5] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
[6] Leiden Univ Med Ctr, Dept Nephrol, Leiden, Netherlands
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年 / 20卷 / 05期
关键词
ADPKD; albuminuria; CKD; MCP-1 (monocyte chemoattractant protein 1); polycystic kidney disease; biomarkers; GROWTH-FACTOR; 23; TOLVAPTAN; PROGRESSION; VASOPRESSIN; MARKER;
D O I
10.2215/CJN.0000000680
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Risk stratification tools for autosomal dominant polycystic kidney disease (ADPKD) predict kidney outcomes on a group level but lack precision in patients. Methods We assessed the value of adding 13 prognostic biomarkers to established risk factors (sex, age, eGFR, systolic BP, Mayo Imaging Classification [MIC], and mutation type) for predicting disease progression. We included 596 patients from the Developing Intervention Strategies to Halt Progression of ADPKD cohort with >= 2 eGFR measurements and >= 1-year follow-up. Results During a mean +/- SD follow-up of 5.0 +/- 2.3 years, the mean +/- SD eGFR slope was -3.46 +/- 2.5 ml/min per 1.73 m(2) per year. Rapid disease progression (eGFR loss >= 3 ml/min per 1.73 m(2) per year) occurred in 303 patients (50.8%), and 279 patients (46.8%) reached the combined end point of kidney failure or 30% eGFR decline. Urinary albumin/creatinine, urinary monocyte chemotactic protein-1/creatinine, and serum copeptin consistently and independently predicted eGFR slope (all P < 0.001), rapid disease progression (area under the curve increasing from 0.79 [95% confidence interval (CI), 0.76 to 0.85] for a baseline model to 0.83 [95% CI, 0.81 to 0.88] when monocyte chemotactic protein-1/creatinine and copeptin were included, P = 0.006), and reaching the combined kidney end point (C-index improving from 0.806 [95% CI, 0.78 to 0.84] for a baseline model to 0.82 [95% CI, 0.79 to 0.85] for a model also containing albumin/creatinine and copeptin, P < 0.001). These results were confirmed in an independent external validation cohort (N=144) and were robust in early disease stages and in patients with moderately increased kidney volumes (MIC 1C). Conclusions Our findings suggest that incorporating these biomarkers into ADPKD risk stratification tools will improve risk prediction, even in subgroups where prognostication is most challenging and relevant.
引用
收藏
页码:608 / 618
页数:11
相关论文
共 38 条
[1]   Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study [J].
Arjune, Sita ;
Oehm, Simon ;
Todorova, Polina ;
Gansevoort, Ron T. ;
Bakker, Stephan J. L. ;
Erger, Florian ;
Benzing, Thomas ;
Burst, Volker ;
Grundmann, Franziska ;
Antczak, Philipp ;
Mueller, Roman-Ulrich .
CLINICAL KIDNEY JOURNAL, 2023, 16 (11) :2194-2204
[2]   Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD [J].
Bais, Thomas ;
Geertsema, Paul ;
Knol, Martine G. E. ;
van Gastel, Maatje D. A. ;
de Haas, Robbert J. ;
Meijer, Esther ;
Gansevoort, Ron T. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (05) :591-601
[3]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[4]   Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease [J].
Cassini, Marcelo F. ;
Kakade, Vijayakumar R. ;
Kurtz, Elizabeth ;
Sulkowski, Parker ;
Glazer, Peter ;
Torres, Richard ;
Somlo, Stefan ;
Cantley, Lloyd G. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (10) :2471-2481
[5]   Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease [J].
Chonchol, Michel ;
Gitomer, Berenice ;
Isakova, Tamara ;
Cai, Xuan ;
Salusky, Isidro ;
Pereira, Renata ;
Abebe, Kaleab ;
Torres, Vicente ;
Steinman, Theodor I. ;
Grantham, Jared J. ;
Chapman, Arlene B. ;
Schrier, Robert W. ;
Wolf, Myles .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (09) :1461-1469
[6]   The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease [J].
Cornec-Le Gall, Emilie ;
Audrezet, Marie-Pierre ;
Rousseau, Annick ;
Hourmant, Maryvonne ;
Renaudineau, Eric ;
Charasse, Christophe ;
Morin, Marie-Pascale ;
Moal, Marie-Christine ;
Dantal, Jacques ;
Wehbe, Batsenn ;
Perrichot, Regine ;
Frouget, Thierry ;
Vigneau, Cecile ;
Potier, Jerome ;
Jousset, Philippe ;
Guillodo, Marie-Paule ;
Siohan, Pascale ;
Terki, Nazim ;
Sawadogo, Theophile ;
Legrand, Didier ;
Menoyo-Calonge, Vittorio ;
Benarbia, Saddik ;
Besnier, Dominique ;
Longuet, Helene ;
Ferec, Claude ;
Le Meur, Yannick .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (03) :942-951
[7]   Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease [J].
Dekker, Shosha E. I. ;
Verhoeven, Aswin ;
Soonawala, Darius ;
Peters, Dorien J. M. ;
de Fijter, Johan W. ;
Mayboroda, Oleg A. .
PLOS ONE, 2020, 15 (05)
[8]   Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease [J].
El Ters, Mireille ;
Lu, Pengcheng ;
Mahnken, Jonathan D. ;
Stubbs, Jason R. ;
Zhang, Shiqin ;
Wallace, Darren P. ;
Grantham, Jared J. ;
Chapman, Arlene B. ;
Torres, Vicente E. ;
Harris, Peter C. ;
Bae, Kyongtae Ty ;
Landsittel, Douglas P. ;
Rahbari-Oskoui, Frederic F. ;
Mrug, Michal ;
Bennett, William M. ;
Yu, Alan S. L. .
KIDNEY INTERNATIONAL REPORTS, 2021, 6 (04) :953-961
[9]   FACTORS AFFECTING THE PROGRESSION OF RENAL-DISEASE IN AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
GABOW, PA ;
JOHNSON, AM ;
KAEHNY, WD ;
KIMBERLING, WJ ;
LEZOTTE, DC ;
DULEY, IT ;
JONES, RH .
KIDNEY INTERNATIONAL, 1992, 41 (05) :1311-1319
[10]   What should European nephrology do with the new CKD-EPI equation? [J].
Gansevoort, Ron T. ;
Anders, Hans-Joachim ;
Cozzolino, Mario ;
Fliser, Danilo ;
Fouque, Denis ;
Ortiz, Alberto ;
Soler, Maria Jose ;
Wanner, Christoph .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (01) :1-6